RAVER1

Summary

RAVER1 (ribonucleoprotein, PTB binding 1, HGNC:30296) is a protein-coding gene on chromosome 19p13.2, encoding Ribonucleoprotein PTB-binding 1 (Q8IY67). Cooperates with PTBP1 to modulate regulated alternative splicing events.

Enables RNA binding activity. Predicted to be located in cytoplasm and nucleus.

Source: NCBI Gene 125950 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 152 total
• Druggable target: yes
• MANE Select transcript: NM_133452

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30296
Approved symbol	RAVER1
Name	ribonucleoprotein, PTB binding 1
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1978
Ensembl gene	ENSG00000161847
Ensembl biotype	protein_coding
OMIM	609950
Entrez	125950

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 11 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000585935, ENST00000591969, ENST00000592208, ENST00000593136, ENST00000617231, ENST00000706673, ENST00000706674, ENST00000910893, ENST00000910894, ENST00000910898, ENST00000910900, ENST00000910901, ENST00000910904, ENST00000910905, ENST00000910906, ENST00000911330, ENST00000911331

RefSeq mRNA: 2 — MANE Select: NM_133452 NM_001366174, NM_133452

CCDS: CCDS45960

Canonical transcript exons

ENST00000617231 — 13 exons

Exon	Start	End
ENSE00001188023	10321048	10321259
ENSE00001301420	10321531	10321618
ENSE00001310430	10330460	10330526
ENSE00001324128	10322645	10322739
ENSE00002901311	10316212	10317600
ENSE00003468546	10320655	10320951
ENSE00003475821	10323145	10323274
ENSE00003477210	10318229	10318372
ENSE00003520343	10317690	10317773
ENSE00003555338	10328642	10329111
ENSE00003617008	10323375	10323566
ENSE00003666897	10319166	10319240
ENSE00003741834	10333289	10333529

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 91.15.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 47.9071 / max 732.1322, expressed in 1821 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
179111	47.6942	1821
179110	0.2128	95

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	91.15	gold quality
mucosa of transverse colon	UBERON:0004991	89.78	gold quality
blood	UBERON:0000178	89.33	gold quality
transverse colon	UBERON:0001157	88.05	gold quality
ventricular zone	UBERON:0003053	87.85	gold quality
left uterine tube	UBERON:0001303	87.70	gold quality
stromal cell of endometrium	CL:0002255	87.66	gold quality
bone marrow cell	CL:0002092	87.64	gold quality
right uterine tube	UBERON:0001302	87.62	gold quality
small intestine Peyer’s patch	UBERON:0003454	87.35	gold quality
small intestine	UBERON:0002108	87.14	gold quality
right ovary	UBERON:0002118	87.00	gold quality
body of uterus	UBERON:0009853	86.96	gold quality
bone marrow	UBERON:0002371	86.38	gold quality
spleen	UBERON:0002106	86.34	gold quality
duodenum	UBERON:0002114	86.15	gold quality
vermiform appendix	UBERON:0001154	85.96	gold quality
left ovary	UBERON:0002119	85.93	gold quality
endocervix	UBERON:0000458	85.80	gold quality
ectocervix	UBERON:0012249	85.74	gold quality
ovary	UBERON:0000992	85.47	gold quality
colon	UBERON:0001155	85.30	gold quality
right coronary artery	UBERON:0001625	85.16	gold quality
leukocyte	CL:0000738	85.13	gold quality
intestine	UBERON:0000160	85.11	gold quality
lower esophagus muscularis layer	UBERON:0035833	85.09	gold quality
body of stomach	UBERON:0001161	85.08	gold quality
lower esophagus	UBERON:0013473	85.08	gold quality
ganglionic eminence	UBERON:0004023	85.04	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	85.02	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.03

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): YY1

miRNA regulators (miRDB)

93 targeting RAVER1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-149-3P	99.72	68.22	3963

Literature-anchored findings (GeneRIF, showing 6)

• Raver1 gene promoter region shares common features of ubiquitously expressed gene with the interacting splicing regulator PTB (PMID:17931803)
• RAVER1 interactions with vinculin and RNA suggest a feed forward pathway in directing messenger RNA to focal adhesions. (PMID:19523901)
• These binding assays show that raver1 forms a ternary complex with metavinculin and vinculin mRNA. (PMID:22709580)
• RAVER1 specifically regulates MDA5 activity, revealing a mechanism of differential regulation of MDA5- and RIG-I-mediated innate antiviral response. (PMID:23390309)
• CRISPRi links COVID-19 GWAS loci to LZTFL1 and RAVER1. (PMID:34998241)
• RAVER1 hinders lethal EMT and modulates miR/RISC activity by the control of alternative splicing. (PMID:38300787)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	raver1	ENSDARG00000052617
mus_musculus	Raver1	ENSMUSG00000010205
rattus_norvegicus	Raver1	ENSRNOG00000020710
drosophila_melanogaster	nito	FBGN0027548

Paralogs (7): SPEN (ENSG00000065526), SFPQ (ENSG00000116560), PSPC1 (ENSG00000121390), NONO (ENSG00000147140), RAVER2 (ENSG00000162437), RBM15 (ENSG00000162775), RBM15B (ENSG00000259956)

Protein

Protein identifiers

Ribonucleoprotein PTB-binding 1 — Q8IY67 (reviewed: Q8IY67)

Alternative names: Protein raver-1

All UniProt accessions (2): A0A087WZ13, K7EKR9

UniProt curated annotations — full annotation on UniProt →

Function. Cooperates with PTBP1 to modulate regulated alternative splicing events. Promotes exon skipping. Cooperates with PTBP1 to modulate switching between mutually exclusive exons during maturation of the TPM1 pre-mRNA.

Subunit / interactions. Interacts with PTBP1, RAVER2, VCL and ACTN1. Part of a complex containing RAVER1, VCL and ACTN1.

Subcellular location. Nucleus. Cytoplasm.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8IY67-1	1	yes
Q8IY67-2	2
Q8IY67-3	3

RefSeq proteins (2): NP_001353103, NP_597709* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034633	RAVER1_RRM1	Domain
IPR034635	RAVER1_RRM3	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR050502	Euk_RNA-bind_prot	Family

Pfam: PF00076

UniProt features (53 total): strand 14, helix 10, modified residue 8, region of interest 5, splice variant 4, turn 4, domain 3, compositionally biased region 2, initiator methionine 1, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
3SMZ	X-RAY DIFFRACTION	1.99
3VF0	X-RAY DIFFRACTION	2.54
3H2U	X-RAY DIFFRACTION	2.75
3H2V	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IY67-F1	68.33	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 2, 6, 14, 463, 474, 562, 488, 567

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 105 (showing top): E2F_Q4, E2F4DP1_01, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, MODULE_453, CACCAGC_MIR138, GTGCCTT_MIR506, CATRRAGC_UNKNOWN, E2F1DP1_01, E2F1DP2_01, LIAO_METASTASIS, CYTAGCAAY_UNKNOWN, E2F1_Q3, MODULE_277, TGCCTTA_MIR124A

GO Biological Process (0):

GO Molecular Function (2): RNA binding (GO:0003723), nucleic acid binding (GO:0003676)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1554 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAVER1	RRM2	P31350	931
RAVER1	VCL	P18206	904
RAVER1	PTBP1	P26599	861
RAVER1	PTBP2	Q9UKA9	843
RAVER1	HNRNPDL	O14979	816
RAVER1	HNRNPC	P07910	779
RAVER1	TPM1	P09493	687
RAVER1	PTBP3	O95758	672
RAVER1	CELF1	Q92879	616
RAVER1	KHSRP	Q92945	578
RAVER1	HNRNPL	P14866	543
RAVER1	PXN	P49023	529
RAVER1	RRM1	P23921	507
RAVER1	SRSF5	Q13243	494
RAVER1	HNRNPA1	P09651	487
RAVER1	NOVA1	P51513	487

IntAct

90 interactions, top by confidence:

A	B	Type	Score
CNOT7	CNOT1	psi-mi:“MI:0914”(association)	0.880
CNOT6L	CNOT1	psi-mi:“MI:0914”(association)	0.810
CNOT11	CNOT1	psi-mi:“MI:0914”(association)	0.770
CNOT3	CNOT1	psi-mi:“MI:0914”(association)	0.740
TOB1	CNOT1	psi-mi:“MI:0914”(association)	0.710
CAPZA2	CNOT1	psi-mi:“MI:0914”(association)	0.640
CAPZB	CNOT1	psi-mi:“MI:0914”(association)	0.640
GRAP2	RAVER1	psi-mi:“MI:0915”(physical association)	0.560
CNOT10	RAVER1	psi-mi:“MI:0915”(physical association)	0.560
SCGN	SNAP23	psi-mi:“MI:0914”(association)	0.550
TOB1	RAVER1	psi-mi:“MI:0914”(association)	0.530
CNOT10	CNOT1	psi-mi:“MI:0914”(association)	0.530
FHL2	CNOT1	psi-mi:“MI:0914”(association)	0.530
BAG2	HGS	psi-mi:“MI:0914”(association)	0.530
FKBP9	CASC3	psi-mi:“MI:0914”(association)	0.530
CFTR	CNOT1	psi-mi:“MI:0914”(association)	0.480
RBM45	HNRNPDL	psi-mi:“MI:0914”(association)	0.460
HTRA2	HAX1	psi-mi:“MI:2364”(proximity)	0.420
Cnot3	CNOT1	psi-mi:“MI:0915”(physical association)	0.400
HIF1AN	CNOT1	psi-mi:“MI:0914”(association)	0.350
ARHGAP36	HAX1	psi-mi:“MI:0914”(association)	0.350
UHMK1	CNOT1	psi-mi:“MI:0914”(association)	0.350
CAPZB	ENAH	psi-mi:“MI:0914”(association)	0.350
hspa1a_hspa1b_human-1	SHTN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (223): RAVER1 (Affinity Capture-MS), RAVER1 (Affinity Capture-MS), RAVER1 (Affinity Capture-MS), RAVER1 (Affinity Capture-MS), RAVER1 (Affinity Capture-MS), RAVER1 (Affinity Capture-MS), RAVER1 (Affinity Capture-MS), PFAS (Co-fractionation), RAVER1 (Co-fractionation), RAVER1 (Co-fractionation), RAVER1 (Co-fractionation), RAVER1 (Co-fractionation), RAVER1 (Co-fractionation), RAVER1 (Co-fractionation), RAVER1 (Affinity Capture-RNA)

ESM2 similar proteins: A0A8I6AGW3, A2A9A2, A2AEV7, A6NEQ2, A6NMB9, A8MYZ6, E9PZZ1, J3QK54, O02755, O02756, O14813, O35392, O35767, O60548, O70220, P05554, P17676, P23813, P42582, P47902, P49715, P49716, P52952, P53566, Q02779, Q03484, Q13461, Q14526, Q3U0S6, Q60843, Q63250, Q63HR2, Q6BEB4, Q6ZQN5, Q70KY4, Q8IU81, Q8IY67, Q8N196, Q90850, Q96HB5

Diamond homologs: A0A0R4IEW8, B3DJT0, F4JHI7, O09032, O22315, O23212, O42847, O43040, P0CP46, P0CP47, P26368, P26369, P26378, P33240, P90727, P90978, P97343, Q12926, Q14576, Q24562, Q28FX0, Q28GD4, Q2HJG2, Q2QKB3, Q2QKB4, Q2QZL4, Q2R0Q1, Q3UEB3, Q5D018, Q5R469, Q5R9Z6, Q5RCY1, Q5RDA3, Q5U259, Q5XI28, Q60899, Q60900, Q61701, Q63285, Q6CEW9

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
RAVER1	“up-regulates activity”	PTBP1	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 112 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain	6	39.9×	1e-06
Deadenylation of mRNA	6	33.8×	2e-06
M-decay: degradation of maternal mRNAs by maternally stored factors	7	29.3×	1e-06
mRNA Splicing	7	9.8×	4e-04
Processing of Capped Intron-Containing Pre-mRNA	8	8.4×	3e-04
mRNA Splicing - Major Pathway	11	7.7×	1e-05
Metabolism of RNA	9	4.8×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
nuclear-transcribed mRNA poly(A) tail shortening	6	46.8×	2e-06
regulatory ncRNA-mediated gene silencing	5	32.7×	8e-05
negative regulation of translation	8	15.2×	2e-05
mRNA splicing, via spliceosome	10	8.9×	5e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

152 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	124
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1639 predictions. Top by Δscore:

Variant	Effect	Δscore
19:10317468:T:TA	donor_gain	1.0000
19:10317684:CCGTA:C	donor_loss	1.0000
19:10317685:CGTA:C	donor_loss	1.0000
19:10317685:CGTAC:C	donor_loss	1.0000
19:10317686:GTAC:G	donor_loss	1.0000
19:10317687:TACC:T	donor_loss	1.0000
19:10317687:TACCT:T	donor_loss	1.0000
19:10317688:ACC:A	donor_loss	1.0000
19:10317770:TTGC:T	acceptor_gain	1.0000
19:10317772:GC:G	acceptor_gain	1.0000
19:10317772:GCC:G	acceptor_loss	1.0000
19:10317773:CC:C	acceptor_gain	1.0000
19:10317773:CCTG:C	acceptor_loss	1.0000
19:10317774:C:CC	acceptor_gain	1.0000
19:10317774:C:CG	acceptor_loss	1.0000
19:10317775:T:A	acceptor_loss	1.0000
19:10317783:A:AC	acceptor_gain	1.0000
19:10318224:CTCA:C	donor_loss	1.0000
19:10318227:ACCTT:A	donor_loss	1.0000
19:10318228:C:CG	donor_loss	1.0000
19:10318228:CCTTA:C	donor_gain	1.0000
19:10318232:A:AC	donor_gain	1.0000
19:10318233:C:CC	donor_gain	1.0000
19:10318370:CAT:C	acceptor_gain	1.0000
19:10318373:C:CC	acceptor_gain	1.0000
19:10318389:G:T	acceptor_gain	1.0000
19:10319163:TACCT:T	donor_loss	1.0000
19:10319164:A:AC	donor_gain	1.0000
19:10319164:A:C	donor_loss	1.0000
19:10319165:C:CC	donor_gain	1.0000

AlphaMissense

4687 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:10328820:A:G	L193P	1.000
19:10328841:G:T	A186D	1.000
19:10328860:A:C	Y180D	1.000
19:10328868:A:G	F177S	1.000
19:10329107:G:C	F97L	1.000
19:10329107:G:T	F97L	1.000
19:10329109:A:G	F97L	1.000
19:10329111:G:T	A96D	1.000
19:10330468:T:A	K93I	1.000
19:10330477:T:A	D90V	1.000
19:10330482:A:C	F88L	1.000
19:10330482:A:T	F88L	1.000
19:10330484:A:G	F88L	1.000
19:10330490:A:G	Y86H	1.000
19:10333311:A:T	L66H	1.000
19:10333320:A:T	I63N	1.000
19:10333326:A:T	I61K	1.000
19:10333328:C:A	K60N	1.000
19:10333328:C:G	K60N	1.000
19:10333333:G:T	R59S	1.000
19:10323394:A:G	L310P	0.999
19:10323531:G:C	F264L	0.999
19:10323531:G:T	F264L	0.999
19:10323533:A:G	F264L	0.999
19:10328739:G:A	S220F	0.999
19:10328779:A:G	W207R	0.999
19:10328779:A:T	W207R	0.999
19:10328828:C:A	K190N	0.999
19:10328828:C:G	K190N	0.999
19:10328832:G:T	A189D	0.999

dbSNP variants (sampled 300 via entrez): RS1000176100 (19:10332020 T>C), RS1000406097 (19:10325905 A>G), RS1000544895 (19:10333036 C>T), RS1000639468 (19:10333737 TG>T), RS1000737969 (19:10327106 A>C,G), RS1000850149 (19:10335514 G>A,C), RS1000868412 (19:10322489 G>A,C,T), RS1000881031 (19:10316684 G>A,C), RS1000932653 (19:10319322 T>C,G), RS1001245362 (19:10317612 G>A,C,T), RS1001605353 (19:10323536 C>T), RS1002138147 (19:10329180 T>A,C,G), RS1002310878 (19:10323731 A>C), RS1002340435 (19:10328785 C>T), RS1002386527 (19:10318455 T>C)

Disease associations

OMIM: gene MIM:609950 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST004131_88	Inflammatory bowel disease	2.000000e-11
GCST004132_111	Crohn’s disease	3.000000e-13
GCST004607_13	Plateletcrit	2.000000e-15
GCST005537_45	Chronic inflammatory diseases (ankylosing spondylitis, Crohn’s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	2.000000e-22
GCST005568_15	Rheumatoid arthritis (ACPA-positive)	2.000000e-14
GCST005569_38	Rheumatoid arthritis	3.000000e-13
GCST009875_18	Type 1 diabetes	5.000000e-10
GCST009877_3	Rheumatoid arthritis	4.000000e-15

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007985	platelet crit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067144 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.90	Kd	12.67	nM	CHEMBL5653589
7.90	ED50	12.67	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149198: Binding affinity to human RAVER1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0127	uM

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	increases expression, affects expression, increases abundance	2
Silicon Dioxide	decreases expression, increases expression	2
Particulate Matter	increases abundance, increases expression	2
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	decreases expression	1
FR900359	affects phosphorylation	1
dicrotophos	increases expression	1
titanium dioxide	increases expression	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
cupric chloride	increases expression	1
diallyl trisulfide	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
ICG 001	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Cadmium	increases abundance, decreases expression	1
Cannabidiol	decreases expression	1
Coumestrol	affects cotreatment, increases expression	1
Dimethyl Sulfoxide	increases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1
Lead	affects expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, decreases expression	1
Ribonucleotides	affects binding	1
Rotenone	decreases expression	1
Valproic Acid	increases methylation	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652240	Binding	Binding affinity to human RAVER1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2DG	Abcam HeLa RAVER1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.